BioFire
In Brief This Week: SD Biosensors, Meridian, Oncocyte, Opko Health, GeneDx, More
News items for the week of Jan. 30, 2023.
BioMérieux Gets Health Canada Approval for Updated BioFire Blood Culture ID Panel
The panel includes additional pathogen targets and resistance genes, as well as revised targets compared to the original BCID panel.
BioMérieux Joint Infection Panel Gets FDA De Novo Authorization
The 39-target panel runs on FilmArray systems and tests for 31 pathogens implicated in most acute joint infections as well as eight antimicrobial resistance genes.
BioMérieux Reports 8 Percent Revenue Growth in Q4
The firm is expecting an overall sales decline in 2022 due to decreased demand for COVID-related products as the disease becomes endemic.
Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.
Sep 1, 2021
BioMérieux H1 Revenues Rise 7 Percent
Aug 31, 2021
Nov 6, 2020
Oct 22, 2020
BioMérieux Q3 Revenues Increase 21 Percent
Feb 26, 2020